MetLife Investment Management’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | – | Sell |
-79,823
| Closed | -$117K | – | 2764 |
|
2025
Q1 | $117K | Buy |
79,823
+41,803
| +110% | +$61K | ﹤0.01% | 2457 |
|
2024
Q4 | $81K | Sell |
38,020
-15,127
| -28% | -$32.2K | ﹤0.01% | 2688 |
|
2024
Q3 | $149K | Sell |
53,147
-5,993
| -10% | -$16.8K | ﹤0.01% | 2438 |
|
2024
Q2 | $138K | Buy |
59,140
+10,140
| +21% | +$23.6K | ﹤0.01% | 2453 |
|
2024
Q1 | $219K | Buy |
49,000
+6,982
| +17% | +$31.2K | ﹤0.01% | 2153 |
|
2023
Q4 | $135K | Hold |
42,018
| – | – | ﹤0.01% | 2456 |
|
2023
Q3 | $133K | Hold |
42,018
| – | – | ﹤0.01% | 2434 |
|
2023
Q2 | $209K | Hold |
42,018
| – | – | ﹤0.01% | 2252 |
|
2023
Q1 | $208K | Hold |
42,018
| – | – | ﹤0.01% | 2198 |
|
2022
Q4 | $264K | Hold |
42,018
| – | – | ﹤0.01% | 2070 |
|
2022
Q3 | $454K | Buy |
42,018
+1,668
| +4% | +$18K | ﹤0.01% | 1710 |
|
2022
Q2 | $460K | Buy |
40,350
+4,024
| +11% | +$45.9K | ﹤0.01% | 1723 |
|
2022
Q1 | $331K | Buy |
36,326
+13,419
| +59% | +$122K | ﹤0.01% | 2038 |
|
2021
Q4 | $342K | Hold |
22,907
| – | – | ﹤0.01% | 1724 |
|
2021
Q3 | $589K | Hold |
22,907
| – | – | 0.01% | 1439 |
|
2021
Q2 | $597K | Hold |
22,907
| – | – | 0.01% | 1466 |
|
2021
Q1 | $809K | Hold |
22,907
| – | – | 0.01% | 1261 |
|
2020
Q4 | $578K | Hold |
22,907
| – | – | 0.01% | 1416 |
|
2020
Q3 | $864K | Buy |
22,907
+1,351
| +6% | +$50.9K | 0.01% | 1101 |
|
2020
Q2 | $923K | Buy |
21,556
+3,547
| +20% | +$152K | 0.01% | 1071 |
|
2020
Q1 | $350K | Hold |
18,009
| – | – | ﹤0.01% | 1408 |
|
2019
Q4 | $468K | Hold |
18,009
| – | – | ﹤0.01% | 1505 |
|
2019
Q3 | $491K | Hold |
18,009
| – | – | 0.01% | 1432 |
|
2019
Q2 | $484K | Buy |
18,009
+5,373
| +43% | +$144K | 0.01% | 1497 |
|
2019
Q1 | $365K | Hold |
12,636
| – | – | ﹤0.01% | 1639 |
|
2018
Q4 | $340K | Buy |
+12,636
| New | +$340K | ﹤0.01% | 1600 |
|